Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.
Also called NCT07659574
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Registry
-
NCT07659574
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07659574. Randomized; triple masking; primary purpose treatment. Start 2026-09-07 (actual); primary completion 2027-09-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)
- Acronym
- UNIGUIDE-1
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- UBT251 Injection 2.0 mg
- Intervention (Drug)
- UBT251 Injection 4.0 mg
- Intervention (Drug)
- UBT251 Injection 6.0 mg
- Intervention (Drug)
- UBT251 Injection Placebo 2.0 mg
- Intervention (Drug)
- UBT251 Injection Placebo 4.0 mg
- Intervention (Drug)
- UBT251 Injection Placebo 6.0 mg
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Record details
- Record id
cardio:ct-nct07659574- Content hash
6b8c141c27d72f3eda308395b802c051350d4fc2dba386fc97d771b97deae12d